Konstantinos Tryfonidis
- Cancer Research top 2%
- Breast Cancer Treatment Studies 28
- Cancer Genomics and Diagnostics 6
- Oncology top 2%
- HER2/EGFR in Cancer Research 18
- Cancer Immunotherapy and Biomarkers 13
- Cancer Treatment and Pharmacology 12
- Cancer Cells and Metastasis 6
-
- Advanced Breast Cancer Therapies 18
-
- BRCA gene mutations in cancer 5
Konstantinos Tryfonidis
53 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Cancer Research 771
- Oncology 1.1k
- Pathology and Forensic Medicine 233
- Pulmonary and Respiratory Medicine 406
- Immunology 202
Countries citing papers authored by Konstantinos Tryfonidis
This map shows the geographic impact of Konstantinos Tryfonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantinos Tryfonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantinos Tryfonidis more than expected).
Fields of papers citing papers by Konstantinos Tryfonidis
This network shows the impact of papers produced by Konstantinos Tryfonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantinos Tryfonidis. The network helps show where Konstantinos Tryfonidis may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Konstantinos Tryfonidis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522breakdown → | 2024 | 47 |
| 2 | 2024 | 2 | |
| 3 | 2024 | 5 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 20 | |
| 6 | 2023 | 67 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 8 | |
| 9 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 studybreakdown → | 2020 | 279 |
| 10 | 2019 | 4 | |
| 11 | 2018 | 1 | |
| 12 | 2018 | 81 | |
| 13 | 2017 | 10 | |
| 14 | 2017 | 10 | |
| 15 | 2017 | 2 | |
| 16 | 2017 | 68 | |
| 17 | 2017 | 98 | |
| 18 | 2016 | 2 | |
| 19 | 2015 | 116 | |
| 20 | 2014 | 8 |
About Konstantinos Tryfonidis
Konstantinos Tryfonidis is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 53 papers that have together received 1.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (28 papers), Advanced Breast Cancer Therapies (18 papers), HER2/EGFR in Cancer Research (18 papers), Cancer Immunotherapy and Biomarkers (13 papers), Cancer Treatment and Pharmacology (12 papers), Cancer Cells and Metastasis (6 papers), Cancer Genomics and Diagnostics (6 papers) and BRCA gene mutations in cancer (5 papers). The work is most often cited by research in Cancer Research (771 citations), Oncology (1.1k citations) and Pathology and Forensic Medicine (233 citations). Konstantinos Tryfonidis has collaborated with scholars based in Belgium, United States and Portugal. Frequent co-authors include Fátima Cardoso, Dimitrios Zardavas, Elżbieta Senkus, Martine Piccart, Leen Slaets, Javier Cortés, Maria João Cardoso, Rebecca Dent, Benita S. Katzenellenbogen and Y.H. Park. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.